These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 21040538)

  • 21. Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria.
    Rabbani N; Adaikalakoteswari A; Rossing K; Rossing P; Tarnow L; Parving HH; Thornalley PJ
    Amino Acids; 2012 May; 42(5):1627-39. PubMed ID: 21384133
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study.
    Persson F; Rossing P; Hovind P; Stehouwer CD; Schalkwijk CG; Tarnow L; Parving HH
    Scand J Clin Lab Invest; 2008; 68(8):731-8. PubMed ID: 18609080
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term effects of Irbesartan treatment and smoking on nucleic acid oxidation in patients with type 2 diabetes and microalbuminuria: an Irbesartan in patients with type 2 diabetes and Microalbuminuria (IRMA 2) substudy.
    Broedbaek K; Henriksen T; Weimann A; Petersen M; Andersen JT; Afzal S; Jimenez-Solem E; Persson F; Parving HH; Rossing P; Poulsen HE
    Diabetes Care; 2011 May; 34(5):1192-8. PubMed ID: 21454798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis.
    Palmer AJ; Valentine WJ; Ray JA
    Int J Clin Pract; 2007 Oct; 61(10):1626-33. PubMed ID: 17877649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease.
    Palmer AJ; Annemans L; Roze S; Lamotte M; Lapuerta P; Chen R; Gabriel S; Carita P; Rodby RA; de Zeeuw D; Parving HH
    Diabetes Care; 2004 Aug; 27(8):1897-903. PubMed ID: 15277414
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects?
    Weldegiorgis M; de Zeeuw D; Dwyer JP; Mol P; Heerspink HJL
    Clin J Am Soc Nephrol; 2017 Oct; 12(10):1595-1600. PubMed ID: 28923834
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns.
    Rossing K; Mischak H; Parving HH; Christensen PK; Walden M; Hillmann M; Kaiser T
    Kidney Int; 2005 Jul; 68(1):193-205. PubMed ID: 15954909
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renoprotection and renin-angiotensin system blockade in diabetes mellitus.
    Ruilope LM
    Am J Hypertens; 1997 Dec; 10(12 Pt 2):325S-331S. PubMed ID: 9438777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Irbesartan: a review of its use in hypertension and diabetic nephropathy.
    Croom KF; Plosker GL
    Drugs; 2008; 68(11):1543-69. PubMed ID: 18627212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A clinical trial in type 2 diabetic nephropathy.
    Lewis EJ; Hunsicker LG; Rodby RA;
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S191-4. PubMed ID: 11576953
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention and treatment of diabetic nephropathy: the program for irbesartan mortality and morbidity evaluation.
    Ravera M; Ratto E; Vettoretti S; Parodi D; Deferrari G
    J Am Soc Nephrol; 2005 Mar; 16 Suppl 1():S48-52. PubMed ID: 15938034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trial.
    Hellemons ME; Persson F; Bakker SJ; Rossing P; Parving HH; De Zeeuw D; Lambers Heerspink HJ
    Diabetes Care; 2011 Sep; 34(9):2078-83. PubMed ID: 21788629
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.
    Rodby RA; Rohde RD; Clarke WR; Hunsicker LG; Anzalone DA; Atkins RC; Ritz E; Lewis EJ
    Nephrol Dial Transplant; 2000 Apr; 15(4):487-97. PubMed ID: 10727543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy].
    Palmer AJ; Roze S; Rodby RA; Valentine WJ; Ritz E; Lehnert H
    Dtsch Med Wochenschr; 2006 Aug; 131(31-32):1721-6. PubMed ID: 16868875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Microalbuminuria in hypertensive patients: evaluation of one-year treatment with irbesartan.
    de Alvaro F; Velasco O; Honorato J; Calvo C; Parrondo I;
    Kidney Int Suppl; 2005 Jan; (93):S29-34. PubMed ID: 15613064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
    Lewis EJ; Hunsicker LG; Clarke WR; Berl T; Pohl MA; Lewis JB; Ritz E; Atkins RC; Rohde R; Raz I;
    N Engl J Med; 2001 Sep; 345(12):851-60. PubMed ID: 11565517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Observational study of blood pressure control and microalbuminuria in type 2 diabetics on irbesartan or irbesartan/HCTZ].
    Schmieder RE; Krekler M
    MMW Fortschr Med; 2005 Oct; 147 Suppl 3():97-101. PubMed ID: 16261944
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Irbesartan reduces creatinine clearance in type 1 diabetic children with renal hyperfunction: a randomized, double-blind, placebo-controlled trial.
    Salcedo-Alejos M; Banda-Espinoza F; Rodríguez-Morán M; Guerrero-Romero F
    Nephrol Dial Transplant; 2005 Oct; 20(10):2120-5. PubMed ID: 16091379
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of amlodipine, efonidipine, and trichlormethiazide on home blood pressure and upper-normal microalbuminuria assessed by casual spot urine test in essential hypertensive patients.
    Hosaka M; Inoue R; Satoh M; Watabe D; Hanazawa T; Ohkubo T; Asayama K; Obara T; Imai Y;
    Clin Exp Hypertens; 2018; 40(5):468-475. PubMed ID: 29172732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria: response to Andersen, Brochner-Mortensen, and Parving.
    Kaiser T; Florack C; Sawicki PT
    Diabetes Care; 2004 Jun; 27(6):1521; author reply 1521-2. PubMed ID: 15161820
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.